ENLIVEN THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $28.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-03
- ENLIVEN THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $28.60M, a 36.84% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $20.90M.
- ENLIVEN THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $14.80M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $28.60M 10-K · filed 2026-03-03 | |
| 2024-12-31 | $20.90M 10-K · filed 2026-03-03 | |
| 2022-12-31 | $10.10M 8-K · filed 2023-06-23 | $700.00K 10-K · filed 2023-02-10 |
| 2021-12-31 | $6.70M 8-K · filed 2023-06-23 | $16.60M 10-K · filed 2022-03-15 |
| 2020-12-31 | $14.80M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |